TY - JOUR
T1 - Novel Biomarkers of Kidney Disease in Advanced Heart Failure
T2 - Beyond GFR and Proteinuria
AU - Roehm, Bethany
AU - McAdams, Meredith
AU - Hedayati, S. Susan
N1 - Funding Information:
Meredith McAdams is supported by training grant 5T32DK007257-38 from the National Institutes of Diabetes and Digestive and Kidney Diseases. S. Susan Hedayati is supported by grant 1R38HL150214 from the National Health, Lung, and Blood Institute and by grant AHA923721 from the American Heart Association. She is also supported by the Yin Quan-Yuen Distinguished Professorship in Nephrology at the University of Texas Southwestern Medical Center, Dallas, Texas.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/8
Y1 - 2022/8
N2 - Purpose: Kidney disease is a common finding in patients with heart failure and can significantly impact treatment decisions and outcomes. Abnormal kidney function is currently determined in clinical practice using filtration markers in the blood to estimate glomerular filtration rate, but the manifestations of kidney disease in the setting of heart failure are much more complex than this. In this manuscript, we review novel biomarkers that may provide a more well-rounded assessment of kidney disease in patients with heart failure. Recent Findings: Galectin-3, ST2, FGF-23, suPAR, miRNA, GDF-15, and NAG may be prognostic of kidney disease progression. L-FABP and suPAR may help predict acute kidney injury (AKI). ST2 and NAG may be helpful in diuretic resistance. Summary: Several biomarkers may be useful in determining prognosis of long-term kidney disease progression, prediction of AKI, and development of diuretic resistance. Further research into the mechanisms of kidney disease in heart failure utilizing many of these biomarkers may lead to the identification of therapeutic targets.
AB - Purpose: Kidney disease is a common finding in patients with heart failure and can significantly impact treatment decisions and outcomes. Abnormal kidney function is currently determined in clinical practice using filtration markers in the blood to estimate glomerular filtration rate, but the manifestations of kidney disease in the setting of heart failure are much more complex than this. In this manuscript, we review novel biomarkers that may provide a more well-rounded assessment of kidney disease in patients with heart failure. Recent Findings: Galectin-3, ST2, FGF-23, suPAR, miRNA, GDF-15, and NAG may be prognostic of kidney disease progression. L-FABP and suPAR may help predict acute kidney injury (AKI). ST2 and NAG may be helpful in diuretic resistance. Summary: Several biomarkers may be useful in determining prognosis of long-term kidney disease progression, prediction of AKI, and development of diuretic resistance. Further research into the mechanisms of kidney disease in heart failure utilizing many of these biomarkers may lead to the identification of therapeutic targets.
KW - Biomarkers
KW - Cardiorenal
KW - Heart failure
KW - Kidney disease
KW - Kidney function
UR - http://www.scopus.com/inward/record.url?scp=85131005047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131005047&partnerID=8YFLogxK
U2 - 10.1007/s11897-022-00557-y
DO - 10.1007/s11897-022-00557-y
M3 - Article
C2 - 35624386
AN - SCOPUS:85131005047
SN - 1546-9530
VL - 19
SP - 223
EP - 235
JO - Current Heart Failure Reports
JF - Current Heart Failure Reports
IS - 4
ER -